Precision Bio, Agrivida Collaborate
News Mar 11, 2014
Precision BioSciences and Agrivida revealed that they have entered into a trait development collaboration based on precise gene modifications made possible by Precision’s Directed Nuclease EditorTM (DNE) Technology.
Agrivida is very pleased with the functional performance of Precision’s DNE technology. “The efficiency, ease-of-use, and the demonstrated utility of the technology confirm the important role that precise genome engineering will have in the future of agricultural biotechnology”, says Mike Lanahan, Agrivida VP of Business Development, Animal Nutrition. “Agrivida anticipates ongoing trait development using the technology in the collaboration with Precision.”
“Precision is excited by Agrivida’s results and we are thrilled to be working with an innovator in animal nutrition such as Agrivida,” says Matthew Kane, Precision CEO. “We are optimistic that the combination Agrivida’s unique understanding of plant metabolism and Precision’s DNE gene editing technology can be utilized to develop a strong pipeline of greatly needed agricultural product candidates.”
Dan Meagher, Agrivida CEO, says, “The opportunity for improving the nutritional characteristics of crops for the dairy and beef market segments is significant. Our results indicate that Precision technology has delivered a compositional modification that will benefit the industry by increasing the productivity of ruminant animals that consume plants expressing our trait.”
Giant Viruses Invent Their Own GenesNews
Three new members have been isolated and added to the Pandoravirus family. This strange family of viruses, with their giant genomes and many genes with no known equivalents, surprised scientists when they were discovered a few years ago. This new study notes that pandoraviruses appear to be factories for new genes – and therefore new functions.
Therapeutic CRISPR Could Be Cancer RiskNews
Therapeutic use of gene editing with the so-called CRISPR-Cas9 technique may inadvertently increase the risk of cancer, according to a new study. Researchers say that more studies are required in order to guarantee the safety of these ‘molecular scissors’ for gene-editing therapies.